Cassava Sciences Inc. (SAVA)
2.70
-0.08 (-2.88%)
At close: Feb 20, 2025, 3:59 PM
2.74
1.44%
After-hours: Feb 20, 2025, 07:05 PM EST
undefined% (undefined)
| Bid | 2.7 |
| Market Cap | 129.90M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.38 |
| PE Ratio (ttm) | -1.96 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2.74 |
| Volume | 1,308,498 |
| Avg. Volume (20D) | 5,771,284 |
| Open | 2.77 |
| Previous Close | 2.78 |
| Day's Range | 2.68 - 2.84 |
| 52-Week Range | 2.23 - 42.20 |
| Beta | undefined |
About SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sci...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 14, 2000
Employees 29
Stock Exchange NASDAQ
Ticker Symbol SAVA
Website https://www.cassavasciences.com
Analyst Forecast
According to 3 analyst ratings, the average rating for SAVA stock is "Hold." The 12-month stock price forecast is $111.5, which is an increase of 4029.63% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
2 months ago
-10.93%
Cassava Sciences shares are trading lower after HC...
Unlock content with
Pro Subscription
2 months ago
+13.76%
Cassava Sciences shares are trading lower after the company announced Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study.
